Metastatic breast cancer trials recruiting in Connecticut

All Metastatic breast cancer trials nationally

Cities in Connecticut

Recruiting trials in Connecticut

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer
  NCT07524855 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · Connecticut: New Haven
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
  NCT06551220 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: Female · Connecticut: New Haven
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
  NCT07340541 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
  NCT03808337 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Hartford, Norwalk
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · Connecticut: New Haven
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
  NCT06072612 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
  NCT06377852 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · Connecticut: Derby, Fairfield, Glastonbury, Greenwich